Welcome to our dedicated page for Eyenovia SEC filings (Ticker: EYEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Eyenovia’s SEC paperwork can feel as precise—and as daunting—as the microdosed spray that powers its Optejet platform. Between clinical-trial disclosures, patent updates and detailed R&D spend, the company’s 10-K and 10-Q reports often bury the numbers that determine whether a new ophthalmic therapy reaches patients. Stock Titan surfaces those data points instantly, turning 200-page documents into clear takeaways so you can focus on the real question investors ask every quarter: how far is Eyenovia from commercializing its next eye-care breakthrough?
Whether you need the full Eyenovia quarterly earnings report 10-Q filing, an Eyenovia annual report 10-K simplified, or an Eyenovia 8-K material events explained, our platform delivers every form the moment it hits EDGAR. AI-generated highlights reveal trial milestones, cash runway and Optejet licensing revenue, while real-time alerts flag Eyenovia insider trading Form 4 transactions. Looking for management incentives? The latest Eyenovia proxy statement executive compensation is decoded so you understand option grants without reading footnotes.
Here’s how professionals use these insights:
- Track Eyenovia Form 4 insider transactions real-time to spot executive buying or selling before pivotal data releases.
- Compare segment spending with our Eyenovia earnings report filing analysis and gauge burn-rate against trial timelines.
- Save hours understanding Eyenovia SEC documents with AI—from risk factor shifts to pipeline progress.
Stop scrolling through PDFs. Every Eyenovia SEC filings explained simply page blends human expertise with AI so you see the story behind the numbers—fast.
Eyenovia, Inc. (Nasdaq: EYEN) has filed a Prospectus Supplement under Form 424B5 to update its existing at-the-market (ATM) equity program with Chardan Capital Markets. The filing registers the offer and sale of up to $14,942,887 in additional common stock, a figure calculated to comply with General Instruction I.B.6 of Form S-3.
• As of 27 June 2025, the company’s non-affiliate public float was approximately $52.8 million, based on 4,853,092 shares at $10.88 per share.
• I.B.6 limits primary offerings to one-third of that float—about $17.6 million—within any 12-month period when the float is under $75 million.
• Eyenovia has already sold $2.66 million of securities during the preceding 12 months, leaving capacity for the newly registered $14.94 million.
The filing does not alter the total $50 million ceiling of the December 30, 2024 amended Sales Agreement, but it refreshes the amount currently eligible for issuance. Shares will be sold from time to time through Chardan acting as sales agent, at market prices on Nasdaq Capital Market under the symbol EYEN.
The supplement reiterates that investment in EYEN entails a high degree of risk and directs investors to previously filed risk factors in the company’s 10-K and 8-K dated 27 June 2025.
Eyenovia, Inc. (NASDAQ: EYEN) has filed a Form 8-K to disclose two material developments:
- Cryptocurrency Treasury Strategy: The Company is launching a long-term program to accumulate, stake and actively deploy HYPE—the native token of the Hyperliquid layer-1 blockchain. Plans include (i) running a co-branded Hyperliquid validator in partnership with Kinetiq and infrastructure provider Pier Two, (ii) offering delegated staking services that could lower users’ trading fees or share referral revenue, and (iii) allocating HYPE to on-chain lending and liquidity strategies via the HyperEVM.
- Business & Technology Update: Eyenovia reiterates progress on its core ophthalmic platform, the Optejet User Filled Device, highlighting clinical data that show 98% first-attempt delivery accuracy and a fivefold reduction in drop volume versus traditional eye drops.
The filing furnishes a related press release (Exhibit 99.1) under Regulation FD and supplements the Company’s prior Form 10-K disclosures with an extensive set of risk factors tied to HYPE price volatility, competitive blockchain dynamics, regulatory scrutiny and potential disruptions at digital-asset service providers.
No financial results, earnings guidance or capital allocation figures are provided; the disclosure is strategic in nature and does not constitute ‘‘filed’’ information under Exchange Act Section 18.
Eyenovia announced a significant strategic shift through a $50 million private placement and entry into cryptocurrency markets. The company sold 5,128,205 shares of Series A Non-Voting Preferred Stock and warrants to institutional investors, with each preferred share convertible into three common shares.
Key developments include:
- Appointment of Hyunsu Jung (age 29) as Chief Investment Officer and Director, with a $250,000 salary and equity incentives
- Plans to build reserves of HYPE tokens and implement a staking program while continuing development of Gen-2 Optejet Device
- Board restructuring with resignations of Sean Ianchulev, Charles Mather IV, and Ram Palanki
- Amendment to loan agreement with Avenue Capital, extending maturity to 2028 and reducing interest from 12% to 8%
The private placement includes warrants exercisable at $3.25 per share after six months, with Chardan Capital Markets acting as placement agent. The company's pro forma shares outstanding would increase to 54,027,429 upon full conversion of preferred shares and warrant exercise.
Avenue Capital Management II has filed a Schedule 13D/A (Amendment No. 3) regarding their holdings in Eyenovia, reporting significant ownership changes through multiple investment vehicles. The filing reveals:
Key Investment Vehicles & Holdings:
- Avenue Venture Opportunities Fund L.P. owns 174,175 shares (4.0%)
- Avenue Venture Opportunities Fund II L.P. holds 261,263 shares (5.99%)
- Avenue Capital Management II L.P. controls 435,438 shares (9.99%)
The funds collectively hold warrants to purchase an additional 250,000 shares at $4.00 per share, though these are subject to a 9.99% beneficial ownership blocker. Total shares outstanding as of June 5, 2025: 4,358,755. Avenue Capital Management II L.P. serves as the manager with sole voting and dispositive power over all securities held by the funds.
FAQ
What is the current stock price of Eyenovia (EYEN)?
What is the market cap of Eyenovia (EYEN)?
What is the core focus of Eyenovia Inc?
How does Eyenovia differentiate its product delivery methods?
Which ocular conditions are targeted by Eyenovia's therapies?
What are the advantages of microdosing in ophthalmic treatments?
How does Eyenovia contribute to advancements in ophthalmic technology?
What is the significance of the Optejet platform for the company?
